Muscle mass and bleeding risk in older adults on blood thinners
Part of Brain & nervous system clinical trials.
This study looks at whether having less muscle mass raises the risk of serious bleeding in older people who take apixaban or rivaroxaban. The study compares those who have had bleeding to those who haven't, to help doctors reduce future bleeding risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older
- You take apixaban (Eliquis) or rivaroxaban (Xarelto) for blood thinning
- You have been hospitalized for a bleeding event (or, for comparison, you have not had any bleeding events)
- You do not have a pacemaker or defibrillator
- You can lie flat on your back for the measurement
- You do not have a digestive condition that affects nutrient absorption (like celiac disease or a stoma)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of the blood thinner edoxaban can safely prevent another stroke in people aged 80 or older who have atrial fibrillation (an irregular heartbeat) and have already had a stroke or mini-stroke. It may be an option for those at higher risk of bleeding.
This study tests a blood thinner (rivaroxaban) versus usual care to see if it can prevent strokes in older adults with extra heartbeats (a sign of possible heart rhythm problems) and high stroke risk. If you qualify, the treatment might reduce your chances of having a stroke.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This study checks whether giving community pharmacists information about your kidney function when they fill your blood-thinner prescription can help reduce bleeding problems. If you take a direct oral anticoagulant (like apixaban or rivaroxaban), your participation could help improve how these medicines are managed safely.
Hear when a new Elderly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.